Brought to you by 
Pfizer to apply Xencor's technologies to its own antibodies
15 Apr 2009
Executive Summary
Antibody therapeutics company Xencor licensed Pfizer rights to use its Xtend and XmAb technologies to optimize its own monoclonal antibody candidates.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com